Physician profile
Prema M Jacob
NPI 1487633533
$7,675.75
in general payments reported to CMS, 2019-2025
53 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $1,374 · 2021: $150 · 2022: $980 · 2023: $2,110 · 2024: $1,156 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,904 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600 · Education: $29.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
| Education | $29.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,243.04 | 2021-2025 | |
| Medtronic Minimed, INC. | $1,147.73 | 2019-2020 | |
| Abbott Laboratories | $626.80 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Eko Health, INC. | $600.00 | 2023 | |
| Lilly USA, LLC | $419.56 | 2021-2025 | Zepbound, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $384.87 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Insulet Corporation | $384.10 | 2022-2025 | Omnipod, Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $333.64 | 2022-2025 | |
| Medtronic, INC. | $291.64 | 2021-2023 | Minimed 780g |
| Amgen INC. | $222.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $209.64 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.35 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $163.35 | 2019-2025 | |
| Novo Nordisk INC | $135.23 | 2022-2025 | Wegovy, Saxenda |
| Pfizer INC. | $132.84 | 2019-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prema Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.